HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) Given Buy Rating at HC Wainwright

HC Wainwright reiterated their buy rating on shares of HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) in a research note issued to investors on Wednesday, November 8th. They currently have a $6.00 target price on the medical research company’s stock.

A number of other brokerages have also recently weighed in on HTGM. ValuEngine upgraded shares of HTG Molecular Diagnostics from a strong sell rating to a sell rating in a research note on Monday, October 23rd. Zacks Investment Research upgraded shares of HTG Molecular Diagnostics from a sell rating to a hold rating in a research note on Tuesday, July 18th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the stock. HTG Molecular Diagnostics presently has a consensus rating of Hold and a consensus target price of $5.25.

Shares of HTG Molecular Diagnostics (HTGM) opened at $2.12 on Wednesday. HTG Molecular Diagnostics has a one year low of $1.20 and a one year high of $13.25.

COPYRIGHT VIOLATION WARNING: “HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) Given Buy Rating at HC Wainwright” was originally reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this article on another site, it was copied illegally and republished in violation of international trademark & copyright law. The original version of this article can be accessed at https://ledgergazette.com/2017/11/17/htg-molecular-diagnostics-inc-htgm-receives-buy-rating-from-hc-wainwright.html.

In other news, major shareholder Holdings A/S Novo sold 1,149,813 shares of the business’s stock in a transaction on Friday, August 25th. The shares were sold at an average price of $1.81, for a total value of $2,081,161.53. The sale was disclosed in a filing with the SEC, which is available at this link. Insiders sold a total of 1,661,889 shares of company stock worth $3,077,980 in the last three months. Insiders own 7.60% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. UBS Group AG acquired a new position in HTG Molecular Diagnostics during the 1st quarter worth about $137,000. Vanguard Group Inc. grew its stake in shares of HTG Molecular Diagnostics by 38.9% during the 2nd quarter. Vanguard Group Inc. now owns 135,234 shares of the medical research company’s stock worth $359,000 after acquiring an additional 37,841 shares in the last quarter. Finally, Granahan Investment Management Inc. MA grew its stake in shares of HTG Molecular Diagnostics by 488.3% during the 3rd quarter. Granahan Investment Management Inc. MA now owns 416,608 shares of the medical research company’s stock worth $708,000 after acquiring an additional 345,798 shares in the last quarter. Institutional investors and hedge funds own 19.99% of the company’s stock.

About HTG Molecular Diagnostics

HTG Molecular Diagnostics, Inc is a commercial-stage company that develops and markets a technology platform to facilitate the routine use of complex molecular profiling. The Company’s HTG Edge and HTG EdgeSeq platforms, consisting of instrumentation, consumables and software analytics, are used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development.

Receive News & Ratings for HTG Molecular Diagnostics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply